{"id":745646,"date":"2018-10-22T09:30:00","date_gmt":"2018-10-22T09:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/"},"modified":"2025-11-07T01:26:57","modified_gmt":"2025-11-07T06:26:57","slug":"mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/","title":{"rendered":"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose        Tumors Expressed PD-L1 with&nbsp;CPS\u226520 and CPS\u22651 and in Total Patient        Population for KEYTRUDA in Combination with Chemotherapy     <\/p>\n<p class=\"bwalignc\">       KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Survival        Benefit as First-Line Therapy for Head and Neck Cancer that has Recurred        or Metastasized     <\/p>\n<p class=\"bwalignc\">       Results from Pivotal Phase 3 KEYNOTE-048 Trial Presented Today at the        ESMO 2018 Congress during the Presidential Symposium     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentation of interim data from the pivotal<br \/>\n      Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1<br \/>\n      therapy, as both monotherapy and in combination with chemotherapy, for<br \/>\n      the first-line treatment of recurrent or metastatic head and neck<br \/>\n      squamous cell carcinoma (HNSCC). These interim results are being<br \/>\n      presented today during the Presidential Symposium at the ESMO 2018<br \/>\n      Congress (Abstract # LBA8_PR) and are included in the official Press<br \/>\n      Program.\n    <\/p>\n<p>\n      Interim data from KEYNOTE-048 showed KEYTRUDA monotherapy improved<br \/>\n      overall survival (OS), a primary endpoint of the study, by 39 percent<br \/>\n      (HR 0.61 [95% CI, 0.45-0.83]; p=0.0007) in patients whose tumors<br \/>\n      expressed PD-L1 with Combined Positive Score (CPS) \u226520, and by 22<br \/>\n      percent (HR 0.78 [95% CI, 0.64-0.96]; p=0.0086) in patients with CPS\u22651,<br \/>\n      compared to the EXTREME regimen (cetuximab with carboplatin or cisplatin<br \/>\n      plus 5-fluorouracil (5-FU), the current standard of care. In addition,<br \/>\n      KEYTRUDA in combination with chemotherapy (carboplatin or cisplatin plus<br \/>\n      5-FU) (KEYTRUDA combination) demonstrated improved OS compared to the<br \/>\n      EXTREME regimen by 23 percent (HR 0.77 [95% CI, 0.63-0.93]; p=0.0034),<br \/>\n      regardless of PD-L1 expression. At the final analysis, superiority for<br \/>\n      OS will be evaluated for KEYTRUDA monotherapy in the total population<br \/>\n      and KEYTRUDA combination in patients whose tumors express PD-L1 at<br \/>\n      CPS\u226520 and CPS\u22651;&nbsp;at this interim analysis, based upon the prespecified<br \/>\n      testing algorithm, non-inferiority for KEYTRUDA monotherapy in the total<br \/>\n      population was demonstrated and statistical significance was not<br \/>\n      achieved for the KEYTRUDA combination in the subset of patients whose<br \/>\n      tumors expressed PD-L1 at CPS \u226520 or&nbsp;\u22651.&nbsp;Additionally, at this time<br \/>\n      point there was no difference in progression-free-survival (PFS), a dual<br \/>\n      primary endpoint of the study, in any of the groups studied. There were<br \/>\n      no new safety concerns identified with the use of KEYTRUDA in<br \/>\n      KEYNOTE-048.\n    <\/p>\n<p>\n      \u201cIn this study, KEYTRUDA showed the potential to significantly prolong<br \/>\n      survival when used as first-line therapy for patients whose head and<br \/>\n      neck cancer had recurred or spread,\u201d said Dr. Barbara Burtness, lead<br \/>\n      investigator for KEYNOTE-048, professor of medicine at&nbsp;Yale School of<br \/>\n      Medicine and co-director, Development Therapeutics Research Program,<br \/>\n      Yale Cancer Center. \u201dThis is a devastating cancer when it recurs, and<br \/>\n      there has not been any advance in first-line treatment for over a<br \/>\n      decade. It is thrilling to see these new data, which have the potential<br \/>\n      to alter the standard of care in the first-line treatment of head and<br \/>\n      neck cancer.\u201d\n    <\/p>\n<p>\n      \u201cKEYTRUDA is the first anti-PD-1 therapy to show superior overall<br \/>\n      survival as first-line treatment compared to the EXTREME regimen, the<br \/>\n      current standard of care in patients with recurrent or metastatic head<br \/>\n      and neck cancer,\u201d said Dr. Roy Baynes, senior vice president and head of<br \/>\n      Global Clinical Development, chief medical officer, Merck Research<br \/>\n      Laboratories. \u201cRecurrent or metastatic head and neck cancer is a very<br \/>\n      challenging disease. Merck would like to thank the patients and<br \/>\n      investigators for participating in this important study, which is<br \/>\n      helping to advance our understanding of the potential for KEYTRUDA and<br \/>\n      PD-1 inhibition in the first-line setting.\u201d\n    <\/p>\n<p>\n      KEYTRUDA is currently approved in 61 countries for the treatment of<br \/>\n      second-line recurrent or metastatic HNSCC, including the U.S. and<br \/>\n      Europe. Merck plans to file a supplemental Biologics License Application<br \/>\n      (sBLA) with the U.S. Food and Drug Administration (FDA) for a first-line<br \/>\n      indication based on KEYNOTE-048 data and will include data from the<br \/>\n      Phase 3 KEYNOTE-040 trial as supportive data. Based on these results,<br \/>\n      Merck has withdrawn the sBLA for KEYNOTE-040 for KEYTRUDA as a<br \/>\n      second-line treatment in patients with recurrent or metastatic HNSCC,<br \/>\n      which was previously assigned a Prescription Drug User Fee Act (PDUFA)<br \/>\n      or target action date of Dec. 28, 2018. The results from KEYNOTE-048<br \/>\n      will also be submitted to regulatory authorities worldwide.\n    <\/p>\n<p>\n      <b>Study Design and Additional Data from KEYNOTE-048 (Abstract #<\/b> <b>LBA8_PR)<\/b>\n    <\/p>\n<p>\n      KEYNOTE-048, a randomized, open-label Phase 3 trial (ClinicalTrials.gov,<br \/>\n      NCT02358031), evaluated KEYTRUDA monotherapy or KEYTRUDA combination,<br \/>\n      compared with the EXTREME regimen, as first-line treatment in 882<br \/>\n      patients with recurrent or metastatic HSNCC. The dual primary endpoints<br \/>\n      were OS and PFS. The secondary endpoints were PFS (at 6 months and 12<br \/>\n      months), objective response rate (ORR) and time to deterioration in<br \/>\n      Quality of Life Global Health Status\/Quality of Life Scales of the<br \/>\n      European Organization for Research and Treatment of Cancer (EORTC)<br \/>\n      Quality of Life Questionnaire and Safety. Duration of response (DOR) was<br \/>\n      evaluated as part of a pre-specified exploratory analysis. The primary<br \/>\n      and secondary endpoints, as well as exploratory DOR analysis, were<br \/>\n      evaluated in patients whose tumors expressed PD-L1 with CPS \u226520 and CPS<br \/>\n      \u22651, and in the total population, regardless of PD-L1 expression, based<br \/>\n      on a fixed sequential testing strategy. At the time of the analysis, the<br \/>\n      median follow-up was 11.7 months for KEYTRUDA monotherapy, 13.0 months<br \/>\n      for KEYTRUDA combination and 10.7 months for the EXTREME regimen,<br \/>\n      respectively.\n    <\/p>\n<p>\n      In the first comparison group, OS in the CPS \u226520 population was<br \/>\n      significantly longer with KEYTRUDA monotherapy (14.9 months) (n=133)<br \/>\n      compared to the EXTREME regimen (10.7 months) (n=122) (HR 0.61 [95% CI,<br \/>\n      0.45-0.83]; p=0.0007). There was no difference in PFS between the study<br \/>\n      arms (HR 0.99 [95% CI, 0.75-1.29]; p=0.5). ORR was 23.3 percent for<br \/>\n      KEYTRUDA monotherapy and 36.1 percent for the EXTREME regimen,<br \/>\n      respectively. The median DOR was substantially longer with KEYTRUDA<br \/>\n      monotherapy (20.9 months) compared to the EXTREME regimen (4.2 months).\n    <\/p>\n<p>\n      Similarly, OS in the CPS \u22651 population was significantly longer with<br \/>\n      KEYTRUDA monotherapy (12.3 months) (n=257) compared to the EXTREME<br \/>\n      regimen (10.3 months) (n=255) (HR 0.78 [95% CI, 0.64-0.96]; p=0.0086).<br \/>\n      There was no difference in PFS between the study arms (HR 1.16 [95% CI,<br \/>\n      0.96-1.39]). ORR was 19.1 percent for KEYTRUDA monotherapy and 34.9<br \/>\n      percent for the EXTREME regimen, respectively. The median DOR was<br \/>\n      substantially longer with KEYTRUDA (20.9 months) compared to the EXTREME<br \/>\n      regimen (4.5 months).\n    <\/p>\n<p>\n      In the second comparison group, OS in the total population was<br \/>\n      significantly longer with the KEYTRUDA combination (13.0 months) (n=281)<br \/>\n      compared to the EXTREME regimen (10.7 months) (n=278) (HR 0.77 [95% CI,<br \/>\n      0.63-0.93]; p=0.0034). There was no difference in PFS between the study<br \/>\n      arms (HR 0.92; 95% CI, 0.77-1.10). ORR was 35.6 percent for the KEYTRUDA<br \/>\n      combination and 36.3 percent for the EXTREME regimen, respectively. The<br \/>\n      median DOR was longer with KEYTRUDA combination (6.7 months) compared to<br \/>\n      the EXTREME regimen (4.3 months).\n    <\/p>\n<p>\n      There were no new safety concerns identified with the use of KEYTRUDA in<br \/>\n      KEYNOTE-048. Grade 3-5 treatment-related adverse events (TRAEs) occurred<br \/>\n      in 16.7 percent, 71.0 percent and 69.0 percent (n=198\/287) of patients<br \/>\n      in the KEYTRUDA monotherapy, KEYTRUDA combination and the EXTREME<br \/>\n      regimen arms, respectively. TRAEs resulting in discontinuation occurred<br \/>\n      in 4.7 percent, 22.8 percent and 19.9 percent of patients in the<br \/>\n      KEYTRUDA monotherapy, KEYTRUDA combination and the EXTREME regimen arms,<br \/>\n      respectively. There were no TRAEs observed with an incidence of \u226515% in<br \/>\n      the KEYTRUDA monotherapy arm. The most common TRAEs (occurring in \u226515%<br \/>\n      of patients) in the KEYTRUDA combination arm included anemia (48.2%),<br \/>\n      nausea (44.9%), neutropenia (33.0%), fatigue (30.4%), mucosal<br \/>\n      inflammation (27.9%), thrombocytopenia (27.2%), vomiting (27.2%),<br \/>\n      stomatitis (24.3%), decreased appetite (22.5%), platelet count decreased<br \/>\n      (18.5%), diarrhea (17.8%) and neutrophil count decreased (16.7%).\n    <\/p>\n<p>\n      Immune-mediated adverse events in patients receiving KEYTRUDA<br \/>\n      monotherapy or combination therapy were hypothyroidism (18.0% and 15.2%,<br \/>\n      respectively), pneumonitis (6.0% and 5.4%, respectively),<br \/>\n      hyperthyroidism (2.7% and 4.7%, respectively), severe skin reactions<br \/>\n      (2.7% and 0.7%, respectively), infusion reactions (1.3% and 2.2%,<br \/>\n      respectively), colitis (1.0% and 2.5%, respectively), nephritis (0.7% in<br \/>\n      both arms), pancreatitis (0.7% and 0.4%, respectively), hypophysitis<br \/>\n      (0.3% and 0.4%, respectively); hepatitis (0.7% monotherapy only);<br \/>\n      myocarditis and thyroiditis (0.4% each, combination only); and adrenal<br \/>\n      insufficiency, encephalitis and uveitis (0.3% each, monotherapy only).<br \/>\n      Treatment-related deaths occurred in 3 patients in the KEYTRUDA<br \/>\n      monotherapy arm [auto-inflammatory disease, disseminated intravascular<br \/>\n      coagulation, and pneumonitis (n=1 each)]; 10 patients in the KEYTRUDA<br \/>\n      combination arm [septic shock (n=5), cerebral ischemia, hemorrhage,<br \/>\n      interstitial lung disease, sepsis, and tumor hemorrhage (n=1 each)]; and<br \/>\n      8 patients in the EXTREME regimen arm [pneumonia (n=3), sepsis (n=2),<br \/>\n      and hypoxia, osteomyelitis, and pulmonary artery thrombosis (n=1 each)].\n    <\/p>\n<p>\n      <b>Additional Information About KEYNOTE-048<\/b>\n    <\/p>\n<p>\n      KEYNOTE-048 enrolled 882 patients with recurrent or metastatic HSNCC who<br \/>\n      were randomized to one of three regimens as first-line therapy, as<br \/>\n      follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        KEYTRUDA monotherapy (200 mg fixed dosed every three weeks [Q3W]) for<br \/>\n        up to 24 months (n=301); or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        KEYTRUDA (200 mg fixed dose Q3W) in combination with cisplatin (100<br \/>\n        mg\/m<sup>2<\/sup> IV Q3W) or carboplatin (AUC 5 IV Q3W) plus 5-FU (1000<br \/>\n        mg\/m<sup>2<\/sup>\/day IV continuous from Day 1-4 Q3W (maximum six<br \/>\n        cycles), followed by additional KEYTRUDA monotherapy maintenance<br \/>\n        therapy until progression of disease, toxicity or until the patient<br \/>\n        had received a maximum of 24 months total treatment (n=281); or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        EXTREME regimen including cetuximab at a loading dose (400 mg\/m<sup>2<\/sup><br \/>\n        IV) followed by weekly doses (250 mg\/m<sup>2<\/sup> IV) in combination<br \/>\n        with cisplatin (100 mg\/m<sup>2<\/sup> IV Q3W) or carboplatin (AUC 5 IV<br \/>\n        Q3W) plus 5-FU (1000 mg\/m<sup>2<\/sup>\/day IV) continuous from Day 1-4<br \/>\n        Q3W (maximum six cycles), followed by additional cetuximab monotherapy<br \/>\n        maintenance therapy until progression of disease or toxicity (n=300).\n      <\/li>\n<\/ul>\n<p>\n      <b>About Head and Neck Cancer<\/b>\n    <\/p>\n<p>\n      Head and neck cancer describes a number of different tumors that develop<br \/>\n      in or around the throat, larynx, nose, sinuses and mouth. Most head and<br \/>\n      neck cancers are squamous cell carcinomas that begin in the flat,<br \/>\n      squamous cells that make up the thin surface layer of the structures in<br \/>\n      the head and neck. The leading modifiable risk factors for head and neck<br \/>\n      cancer include tobacco and heavy alcohol use. Other risk factors include<br \/>\n      infection with certain types of HPV, also called human papillomaviruses.<br \/>\n      Worldwide, an estimated 835,000 new head and neck cancer cases will be<br \/>\n      diagnosed in 2018, and an estimated 431,000 people will die from the<br \/>\n      disease this year. In the U.S., there were an estimated 63,000 new cases<br \/>\n      diagnosed in 2017.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae&nbsp;<\/b><br \/>\n<\/sup><br \/>\n<b>(pembrolizumab)<br \/>\n      Injection 100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 850 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [Tumor Proportion Score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK<i> <\/i>genomic<br \/>\n      tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin or<br \/>\n      cisplatin, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression. In pediatric<br \/>\n      patients with PMBCL, KEYTRUDA is administered at a dose of 2 mg\/kg (up<br \/>\n      to a maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [Combined Positive Score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is a fixed dose of<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%),<br \/>\n      and occurred more frequently in patients with a history of prior<br \/>\n      thoracic radiation (6.9%) compared to those without (2.9%). Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue for Grade 4<br \/>\n      colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC occurring in 15% (28\/192) of patients. Hyperthyroidism occurred in<br \/>\n      3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and<br \/>\n      thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade 2<br \/>\n      (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients with Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC, with the<br \/>\n      exception of increased incidences of facial edema and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study in 40<br \/>\n      pediatric patients with advanced melanoma, lymphoma, or PD-L1\u2013positive<br \/>\n      advanced, relapsed, or refractory solid tumors, the safety profile was<br \/>\n      similar to that seen in adults treated with KEYTRUDA. Toxicities that<br \/>\n      occurred at a higher rate (\u226515% difference) in these patients when<br \/>\n      compared to adults under 65 years of age were fatigue (45%), vomiting<br \/>\n      (38%), abdominal pain (28%), hypertransaminasemia (28%), and<br \/>\n      hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at <\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and <\/b>\n    <\/p>\n<p>\n      <b>Medication Guide for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181022005244r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Elizabeth        H. Sell, 267-305-3877<br \/>or<br \/>Investors<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of interim data from the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as both monotherapy and in combination with chemotherapy, for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). These interim results are being presented today during the Presidential Symposium at the ESMO 2018 Congress (Abstract # LBA8_PR) and are included in the official Press Program. Interim data from KEYNOTE-048 showed KEYTRUDA monotherapy improved overall survival (OS), a primary endpoint of the study, by 39 percent (HR 0.61 [95% CI, 0.45-0.83]; p=0.0007) in patients whose tumors expressed PD-L1 with Combined Positive Score (CPS) \u226520, and by 22 percent (HR 0.78 [95% CI, 0.64-0.96]; p=0.0086) in patients with CPS\u22651, compared to the EXTREME regimen (cetuximab with carboplatin or cisplatin plus 5-fluorouracil (5-FU),<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,138,289,56],"class_list":["post-745646","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of interim data from the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as both monotherapy and in combination with chemotherapy, for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). These interim results are being presented today during the Presidential Symposium at the ESMO 2018 Congress (Abstract # LBA8_PR) and are included in the official Press Program. Interim data from KEYNOTE-048 showed KEYTRUDA monotherapy improved overall survival (OS), a primary endpoint of the study, by 39 percent (HR 0.61 [95% CI, 0.45-0.83]; p=0.0007) in patients whose tumors expressed PD-L1 with Combined Positive Score (CPS) \u226520, and by 22 percent (HR 0.78 [95% CI, 0.64-0.96]; p=0.0086) in patients with CPS\u22651, compared to the EXTREME regimen (cetuximab with carboplatin or cisplatin plus 5-fluorouracil (5-FU),\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\\\/\",\"name\":\"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-10-22T09:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of interim data from the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as both monotherapy and in combination with chemotherapy, for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). These interim results are being presented today during the Presidential Symposium at the ESMO 2018 Congress (Abstract # LBA8_PR) and are included in the official Press Program. Interim data from KEYNOTE-048 showed KEYTRUDA monotherapy improved overall survival (OS), a primary endpoint of the study, by 39 percent (HR 0.61 [95% CI, 0.45-0.83]; p=0.0007) in patients whose tumors expressed PD-L1 with Combined Positive Score (CPS) \u226520, and by 22 percent (HR 0.78 [95% CI, 0.64-0.96]; p=0.0086) in patients with CPS\u22651, compared to the EXTREME regimen (cetuximab with carboplatin or cisplatin plus 5-fluorouracil (5-FU),","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:57+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/","name":"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-10-22T09:30:00+00:00","dateModified":"2025-11-07T06:26:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-compared-to-standard-of-care-as-monotherapy-and-in-combination-with-chemotherapy-as-first-line-treatment-for-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"235cfe31-4bc0-43da-8602-73ebe500c158","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination--KRPKO.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745646\/revisions"}],"predecessor-version":[{"id":3674997,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745646\/revisions\/3674997"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745646"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}